MedTrace Logo

Improved Glycemic Control in Diabetic Patients in Hemodialysis Using Continuous Glucose Monitoring (CGM)

NCT05678712 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-01-31

No results posted yet for this study

Summary

The 16-week trial is an open-label cross-over trial which includes heamodialysis patients with T2D and T1D on insulin therapy. During one period, patients carry a non-blinded CGM. In the other period they follow standard procedures (the last two weeks with a blinded CGM). The patients and the dialysis staff can use the CGM measures to regulate insulin and food intake during the non-blinded weeks. The research group will collect the CGM-data during the trial.

Conditions

  • Hemodialysis
  • Type1diabetes
  • Type2Diabetes

Interventions

DEVICE

Access to CGM data (Dexcom G6)

Acces to CGM data (not blinded CGM)

Sponsors & Collaborators

  • Steno Diabetes Center Nordjylland

    collaborator OTHER

  • Aalborg University

    collaborator OTHER

  • Aalborg University Hospital

    lead OTHER

Principal Investigators

  • Sisse Heiden Laursen, PhD · Aalborg University

  • Peter Vestergaard, PhD (and MD) · Aalborg University Hospital and Steno Diabetes Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-09
Primary Completion
2023-12-18
Completion
2023-12-18

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05678712 on ClinicalTrials.gov